{"success":true,"data":{"pressRelease":{"id":"77860","rtpr_id":"nGNEbv8Bk9","ticker":"EVAX","exchange":"NASDAQ","all_tickers":["EVAX"],"title":"Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop","author":"Globe Newswire","published_at":"2026-07-01T12:00:00.055Z","article_body":"* New preclinical data will guide antigen selection for a broadly protective\ncytomegalovirus vaccine candidate\n* Poster presentation on July 12, 2026, at the International Herpesvirus\nWorkshop 2026 taking place in Montreal, Canada\nCOPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX)\n(“Evaxion”), a clinical-stage TechBio company developing novel vaccines\nwith its pioneering AI-Immunology™ platform, will present new preclinical\ndata for vaccine candidate EVX-V1 in a poster session at the International\nHerpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15,\n2026.\n\nEVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine\ncandidate combining novel AI-discovered antigens with AI-optimized versions of\nestablished CMV vaccine antigens.\n\nThe new preclinical data will guide final antigen selection for a broadly\nprotective CMV vaccine candidate as we progress the program according to plan.\n\nPresentations details:\nAbstract title: AI-driven multi-antigen vaccine design to address\ncytomegalovirus infection, latency, and immune evasion\nPoster#: P2.63\nSession: Poster session 01\nLocation: Mont-Royal I/II, Centre Mont-Royal\nDate/Time: July 12, 2026, at 9:30-11:30am ET/15:30-17:30\nCET                  \nPresenter: Gry Persson, Senior Project Manager at Evaxion\n\nAbout EVX-V1\nEVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine\ncandidate combining novel AI-discovered antigens with AI-optimized versions of\nestablished CMV vaccine antigens. Through this combination, EVX-V1 attacks the\nvirus from multiple, complementary angles. This broader multi-targeted\nstrategy is expected to strengthen the protective potential of the vaccine.\n\nWith our AI-Immunology™ platform, we have uncovered novel antigens that are\nentirely new to the CMV vaccine research field. These previously unexplored\nCMV-antigens induce specific immune responses, inhibit viral infection and\nreduce cell-to-cell spread in cellular and animal viral infection models.\n\nEVX-V1 is a combination of these antigens with our proprietary AI-optimized\npre-fusion glycoprotein B (gB) antigen which has demonstrated superior\nperformance compared to the traditional gB antigen, including enhanced CMV\nneutralization.\n\nAbout CMV\nAbout 1 in 200 babies is born with congenital CMV infection. About 1 in 5\nbabies with the infection will have congenital disabilities or other long-term\nhealth problems. CMV infects approximately 60% to 70% of adults in developed\ncountries and nearly 100% in developing economies, driving demand for CMV\ntreatment. Despite decades of research, no CMV vaccine has been approved to\ndate.\n\nCMV treatment market size was valued at $474.6 million in 2023 and is\nanticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032.\nThis growth is propelled by increasing awareness and prevalence of CMV\ninfection and the development of new and effective treatments.\n\nCMV is the most complex of all herpes viruses and is a widespread infection\ntransmitted in body fluids. Once infected, the virus stays for life. People\nwith weakened immune systems, including organ transplant patients, can develop\nsevere symptoms affecting, for example, eyes, lungs, and liver, and\ncongenitally infected babies may suffer from intellectual disability and loss\nof vision and hearing.\n\nContact information \nEvaxion A/S\nMads Kronborg\nVice President, Investor Relations & Communication\n+45 53 54 82 96 \nmak@evaxion.ai\n\nAbout Evaxion \nEvaxion is a pioneering TechBio company based upon its proprietary, clinically\nvalidated and scalable AI platform, AI-Immunology™. The platform harnesses\nthe power of artificial intelligence to decode the human immune system and\ndevelop novel vaccine candidates for cancer and infectious diseases.\n\nWith AI-Immunology™ we conduct rapid, efficient and high-quality target\ndiscovery, drug design and development. Our team of +40 experts covers the\nentire value chain from target discovery to clinical development\n\nWe have developed a clinical pipeline of both personalized and off-the-shelf\ncancer vaccine candidates as well as prophylactic vaccine candidates for\ninfectious diseases. All our candidates address high unmet medical needs,\nreflecting our commitment to transforming patients’ lives by providing\ninnovative and targeted treatment options.\n\nFor more information about Evaxion, AI-Immunology™ and our pipeline, please\nvisit our website\n(https://www.globenewswire.com/Tracker?data=m9VOK4qaoKmdh7Yf9OYXTWD1PYOj9iVsEXdAPzOnMA6sQUrKaHUbMou3QG0cWrmVL-SX4oBvramlV1U6D7qh1g==). \n\nForward-looking statement \nThis announcement contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. The words “target,”\n“believe,” “expect,” “hope,” “aim,” “intend,” “may,”\n“might,” “anticipate,” “contemplate,” “continue,”\n“estimate,” “plan,” “potential,” “predict,” “project,”\n“will,” “can have,” “likely,” “should,” “would,”\n“could,” and other words and terms of similar meaning identify\nforward-looking statements. Actual results may differ materially from those\nindicated by such forward-looking statements as a result of various factors,\nincluding, but not limited to, risks related to: our financial condition and\nneed for additional capital; our development work; cost and success of our\nproduct development activities and preclinical and clinical trials;\ncommercializing any approved pharmaceutical product developed using our AI\nplatform technology, including the rate and degree of market acceptance of our\nproduct candidates; our dependence on third parties including for conduct of\nclinical testing and product manufacture; our inability to enter into\npartnerships; government regulation; protection of our intellectual property\nrights; employee matters and managing growth; our ADSs and ordinary\nshares, the impact of international economic, political, legal, compliance,\nsocial and business factors, including inflation, and the effects on\nour business from other significant geopolitical and macro-economic\nevents; and other uncertainties affecting our business operations and\nfinancial condition. For a further discussion of these risks, please refer to\nthe risk factors included in our most recent Annual Report on Form 20-F and\nother filings with the US Securities and Exchange Commission (SEC), which are\navailable at www.sec.gov. We do not assume any obligation to update any\nforward-looking statements except as required by law.","article_body_html":"","raw_payload":{"data":{"id":"nGNEbv8Bk9","title":"Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop","author":"Globe Newswire","ticker":"EVAX","created":"2026-07-01T12:00:00.055Z","tickers":["EVAX"],"exchange":"NASDAQ","article_body":"* New preclinical data will guide antigen selection for a broadly protective\ncytomegalovirus vaccine candidate\n* Poster presentation on July 12, 2026, at the International Herpesvirus\nWorkshop 2026 taking place in Montreal, Canada\nCOPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX)\n(“Evaxion”), a clinical-stage TechBio company developing novel vaccines\nwith its pioneering AI-Immunology™ platform, will present new preclinical\ndata for vaccine candidate EVX-V1 in a poster session at the International\nHerpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15,\n2026.\n\nEVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine\ncandidate combining novel AI-discovered antigens with AI-optimized versions of\nestablished CMV vaccine antigens.\n\nThe new preclinical data will guide final antigen selection for a broadly\nprotective CMV vaccine candidate as we progress the program according to plan.\n\nPresentations details:\nAbstract title: AI-driven multi-antigen vaccine design to address\ncytomegalovirus infection, latency, and immune evasion\nPoster#: P2.63\nSession: Poster session 01\nLocation: Mont-Royal I/II, Centre Mont-Royal\nDate/Time: July 12, 2026, at 9:30-11:30am ET/15:30-17:30\nCET                  \nPresenter: Gry Persson, Senior Project Manager at Evaxion\n\nAbout EVX-V1\nEVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine\ncandidate combining novel AI-discovered antigens with AI-optimized versions of\nestablished CMV vaccine antigens. Through this combination, EVX-V1 attacks the\nvirus from multiple, complementary angles. This broader multi-targeted\nstrategy is expected to strengthen the protective potential of the vaccine.\n\nWith our AI-Immunology™ platform, we have uncovered novel antigens that are\nentirely new to the CMV vaccine research field. These previously unexplored\nCMV-antigens induce specific immune responses, inhibit viral infection and\nreduce cell-to-cell spread in cellular and animal viral infection models.\n\nEVX-V1 is a combination of these antigens with our proprietary AI-optimized\npre-fusion glycoprotein B (gB) antigen which has demonstrated superior\nperformance compared to the traditional gB antigen, including enhanced CMV\nneutralization.\n\nAbout CMV\nAbout 1 in 200 babies is born with congenital CMV infection. About 1 in 5\nbabies with the infection will have congenital disabilities or other long-term\nhealth problems. CMV infects approximately 60% to 70% of adults in developed\ncountries and nearly 100% in developing economies, driving demand for CMV\ntreatment. Despite decades of research, no CMV vaccine has been approved to\ndate.\n\nCMV treatment market size was valued at $474.6 million in 2023 and is\nanticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032.\nThis growth is propelled by increasing awareness and prevalence of CMV\ninfection and the development of new and effective treatments.\n\nCMV is the most complex of all herpes viruses and is a widespread infection\ntransmitted in body fluids. Once infected, the virus stays for life. People\nwith weakened immune systems, including organ transplant patients, can develop\nsevere symptoms affecting, for example, eyes, lungs, and liver, and\ncongenitally infected babies may suffer from intellectual disability and loss\nof vision and hearing.\n\nContact information \nEvaxion A/S\nMads Kronborg\nVice President, Investor Relations & Communication\n+45 53 54 82 96 \nmak@evaxion.ai\n\nAbout Evaxion \nEvaxion is a pioneering TechBio company based upon its proprietary, clinically\nvalidated and scalable AI platform, AI-Immunology™. The platform harnesses\nthe power of artificial intelligence to decode the human immune system and\ndevelop novel vaccine candidates for cancer and infectious diseases.\n\nWith AI-Immunology™ we conduct rapid, efficient and high-quality target\ndiscovery, drug design and development. Our team of +40 experts covers the\nentire value chain from target discovery to clinical development\n\nWe have developed a clinical pipeline of both personalized and off-the-shelf\ncancer vaccine candidates as well as prophylactic vaccine candidates for\ninfectious diseases. All our candidates address high unmet medical needs,\nreflecting our commitment to transforming patients’ lives by providing\ninnovative and targeted treatment options.\n\nFor more information about Evaxion, AI-Immunology™ and our pipeline, please\nvisit our website\n(https://www.globenewswire.com/Tracker?data=m9VOK4qaoKmdh7Yf9OYXTWD1PYOj9iVsEXdAPzOnMA6sQUrKaHUbMou3QG0cWrmVL-SX4oBvramlV1U6D7qh1g==). \n\nForward-looking statement \nThis announcement contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. The words “target,”\n“believe,” “expect,” “hope,” “aim,” “intend,” “may,”\n“might,” “anticipate,” “contemplate,” “continue,”\n“estimate,” “plan,” “potential,” “predict,” “project,”\n“will,” “can have,” “likely,” “should,” “would,”\n“could,” and other words and terms of similar meaning identify\nforward-looking statements. Actual results may differ materially from those\nindicated by such forward-looking statements as a result of various factors,\nincluding, but not limited to, risks related to: our financial condition and\nneed for additional capital; our development work; cost and success of our\nproduct development activities and preclinical and clinical trials;\ncommercializing any approved pharmaceutical product developed using our AI\nplatform technology, including the rate and degree of market acceptance of our\nproduct candidates; our dependence on third parties including for conduct of\nclinical testing and product manufacture; our inability to enter into\npartnerships; government regulation; protection of our intellectual property\nrights; employee matters and managing growth; our ADSs and ordinary\nshares, the impact of international economic, political, legal, compliance,\nsocial and business factors, including inflation, and the effects on\nour business from other significant geopolitical and macro-economic\nevents; and other uncertainties affecting our business operations and\nfinancial condition. For a further discussion of these risks, please refer to\nthe risk factors included in our most recent Annual Report on Form 20-F and\nother filings with the US Securities and Exchange Commission (SEC), which are\navailable at www.sec.gov. We do not assume any obligation to update any\nforward-looking statements except as required by law."},"type":"article","timestamp":"2026-07-01T12:00:00.175955517Z","server_sent_at_ms":1782907200175},"received_at":"2026-07-01T12:00:00.226Z","source_url":"https://www.globenewswire.com/news-release/2026/07/01/3320532/0/en/Evaxion-to-present-new-preclinical-data-for-cytomegalovirus-vaccine-candidate-EVX-V1-at-the-International-Herpesvirus-Workshop.html"},"analysis":{"id":"67105","press_release_id":"77860","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Evaxion announced it will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop in Montreal.\n\nThe data will guide final antigen selection for EVX-V1, a multi-component candidate that combines AI-discovered antigens with established antigens to target viral infection and latency.\n\nNo CMV vaccine has been approved to date; the treatment market was valued at $474.6 million in 2023 and is projected to grow at a 6.6% CAGR through 2032.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Preclinical data presentation for EVX-V1 highlights pipeline progress but remains early-stage."},"keyFigures":{"customDimensions":{"cmv_market_cagr_2024_2032":"6.6%","congenital_infection_rate":"1 in 200","cmv_treatment_market_size_2023":"$474.6 million","adult_prevalence_developed_countries":"60% to 70%","adult_prevalence_developing_economies":"nearly 100%"}},"quotedText":"The new preclinical data will guide final antigen selection for a broadly protective CMV vaccine candidate as we progress the program according to plan.","namedEntities":{"people":[{"name":"Gry Persson","role":"Senior Project Manager"},{"name":"Mads Kronborg","role":"Vice President, Investor Relations & Communication"}],"products":["EVX-V1","AI-Immunology™"],"companies":[{"name":"Evaxion A/S","ticker":"EVAX"}],"dollarAmounts":[{"amount":"$474.6 million","context":"CMV treatment market size in 2023"}]},"materialImpact":{"score":2,"reasoning":"Preclinical data presentation at a scientific workshop; while it validates pipeline progress, it is an early-stage, non-binary event with no immediate regulatory or revenue implications."},"tickerRelevance":{"others":[],"primary":"EVAX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"stage":"preclinical","tickerTier":"small_micro_cap","eventGravity":"scientific_conference_poster"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Evaxion announced it will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop in Montreal.\n\nThe data will guide final antigen selection for EVX-V1, a multi-component candidate that combines AI-discovered antigens with established antigens to target viral infection and latency.\n\nNo CMV vaccine has been approved to date; the treatment market was valued at $474.6 million in 2023 and is projected to grow at a 6.6% CAGR through 2032.","key_figures":{"customDimensions":{"cmv_market_cagr_2024_2032":"6.6%","congenital_infection_rate":"1 in 200","cmv_treatment_market_size_2023":"$474.6 million","adult_prevalence_developed_countries":"60% to 70%","adult_prevalence_developing_economies":"nearly 100%"}},"named_entities":{"people":[{"name":"Gry Persson","role":"Senior Project Manager"},{"name":"Mads Kronborg","role":"Vice President, Investor Relations & Communication"}],"products":["EVX-V1","AI-Immunology™"],"companies":[{"name":"Evaxion A/S","ticker":"EVAX"}],"dollarAmounts":[{"amount":"$474.6 million","context":"CMV treatment market size in 2023"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-01T15:52:16.595Z","global_importance":10,"audience_relevance":15,"importance_components":{"stage":"preclinical","tickerTier":"small_micro_cap","eventGravity":"scientific_conference_poster"}},"durationMs":null,"modelName":"george-droid-qwen-72b"}}